• 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Conclusions br We have shown


    5. Conclusions
    We have shown that it is possible to detect miRNAs in the urinary supernatant and that combining urinary cell-free miRNA and sediment DNA methylation is a valid approach to identify AS patients at increased risk for reclassification. Once validated, our 3-marker panel, with its high NPV, could be used to identify AS patients who are unlikely to reclassify so that they may be monitored less intensely, 
    decreasing morbidity and costs, but further prospective con-firmation will be required.
    [2] Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012;118 (23):5768–76.
    [4] Womble PR, Dixon MW, Linsell SM, Ye Z, Montie JE, Lane BR, et al. Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. J Urol 2014;191
    [5] Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183(3):963–8.
    [6] Ladjevardi S, Auer G, Castro J, Ericsson C, Zetterberg A, Haggman M, et al. Prostate biopsy sampling causes hematogenous dissemina-tion of epithelial cellular material. Dis Markers 2014;2014:707529.
    [9] Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, et al. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 2015;9(5-6):171–8.
    [10] Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stew-art ST, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010;304(21):2373–80.
    [13] Klotz L, Loblaw A, Sugar L, Moussa M, Berman DM, Van der Kwast T, et al. Active surveillance magnetic resonance imaging study (ASIST): results of a randomized multicenter prospective trial. Eur Urol 2019;75 (2):300–9.
    [15] Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, et al. Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J Urol 2018;199(6):1475–81.
    [16] Wu C, Ding X, Li H, Zhu C, Xiong C. Genome-wide Doxorubicin meth-ylation profile of human testis and epididymis: identified from cell-free seminal DNA. BMC Genomics 2013;14:288.
    [17] Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Ven-kateswaran V, et al. Urinary DNA methylation biomarkers for nonin-vasive prediction of aggressive disease in patients with prostate cancer on active surveillance. J Urol 2017;197(2):335–41.
    [18] Zhao F, Jeyapala R, Olkhov-Mitsel E, Vesprini D, Fleshner NE, Bapat B. Re: Urinary DNA methylation biomarkers for noninvasive prediction of aggressive disease in patients with prostate cancer on
    [20] Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, et al. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012;7(9):1037–45.
    [21] Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum microRNA levels associate with absence of high-grade pros-tate cancer in a retrospective cohort. PLoS One 2015;10(4): e0124245.
    [22] Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71(2):550–60.
    [25] Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 2013;8(7):e69239.
    [26] Haldrup C, Kosaka N, Ochiya T, Borre M, Hoyer S, Orntoft TF, et al. Profiling of circulating microRNAs for prostate cancer biomarker dis-covery. Drug Deliv Transl Res 2014;4(1):19–30.
    [28] Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating microRNAs in metastatic cas-tration resistant prostate cancer and low-risk, localized prostate can-cer. Prostate 2013;73(4):346–54.
    [29] Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 2013;14
    [32] Olkhov-Mitsel E, Zdravic D, Kron K, van der Kwast T, Fleshner N, Bapat B. Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. Sci Rep 2014;4:4432.
    [34] Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55(4):611–22.